R2 Technology, a perennial leader in the development of computer-aided detection technology, has received premarket approval from the FDA to sell its ImageChecker CT CAD software in the U.S. An executive for the Sunnyvale, CA, company said marketing
R2 Technology, a perennial leader in the development of computer-aided detection technology, has received premarket approval from the FDA to sell its ImageChecker CT CAD software in the U.S. An executive for the Sunnyvale, CA, company said marketing would begin immediately.
ImageChecker CT CAD is the first CAD product the FDA has approved for the detection of solid lung nodules during review of multislice CT chest exams. Being first gives R2 a distinct advantage, said Susan Wood, vice president of CT products for the firm.
"We have the first-mover advantage to provide a solution to a problem that radiologists have been telling us about. That problem is having too much information," she said. "Our product gives them the means to distill the information, so that they can make a more accurate diagnosis."
R2 believes it will have the only marketable product through at least the remainder of 2004. The company expects to ship about 25 by the end of the year.
As with other R2 products, ImageChecker CT CAD is intended for use after physicians have done the primary reading. CAD algorithms are designed to provide a computerized "second reading," automatically pointing out potential areas of interest. The objectives are to reduce the rate of missed lesions and to increase physician accuracy, particularly in the detection of solid lung nodules.
"We've positioned the product to work for all diagnostic chest exams and for screening," Wood said. "To our software, lung nodules-whether detected as part of a screening or part of a diagnostic exam-look the same. So it's up to purchasers how they want to use the software."
R2's product will provide a financial benefit to users by improving the diagnostic process, Wood said, even though there is no incremental reimbursement for the use of lung CAD.
"Radiologists are being inundated with more and more information," she said. "This device is targeted to increase their accuracy . . . and cut down on their reading time."
The system can be integrated with hospital PACS or CT scanners. While not yet bundled with any CTs, ImageChecker CT CAD can be purchased as an option, Wood said. Installed systems can also be upgraded to include the CAD tool.
ImageChecker CT CAD will be marketed initially to large hospitals that have multiple CT scanners and perceived workflow inefficiencies. Independent radiology centers also will be targeted.
With an estimated 1.2 million new cases each year, lung cancer represents a substantial clinical need. According to the American Cancer Society, many early-stage lung cancers are diagnosed incidentally as a result of imaging studies requested for unrelated medical conditions. Lung CAD software may be well suited for helping to catch these cancers.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.